|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
180,310,000 |
Market
Cap: |
41.24(B) |
Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
52
Week Range: |
$191.51 - $228.9 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
39,326 |
484,602 |
Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,100,996 |
Total People Sold |
0 |
0 |
7 |
8 |
Total Sell Transactions |
0 |
0 |
18 |
70 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Siegall Clay B |
President & CEO |
|
2012-07-02 |
4 |
AS |
$25.36 |
$209,201 |
D/D |
(8,250) |
1,096,711 |
|
- |
|
Siegall Clay B |
President & CEO |
|
2012-07-02 |
4 |
OE |
$3.30 |
$41,285 |
D/D |
8,250 |
1,098,711 |
|
- |
|
Dobmeier Eric |
Chief Operating Officer |
|
2012-06-18 |
4 |
AS |
$25.36 |
$634,000 |
D/D |
(25,000) |
68,073 |
|
- |
|
Dobmeier Eric |
Chief Operating Officer |
|
2012-06-18 |
4 |
OE |
$10.29 |
$257,250 |
D/D |
25,000 |
93,073 |
|
- |
|
Fbb2 Llc |
Director |
|
2012-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
18,243 |
|
- |
|
Simpson Todd E |
Chief Financial Officer |
|
2012-06-14 |
4 |
AS |
$24.97 |
$1,248,500 |
D/D |
(50,000) |
50,762 |
|
- |
|
Simpson Todd E |
Chief Financial Officer |
|
2012-06-14 |
4 |
OE |
$5.20 |
$268,421 |
D/D |
50,000 |
70,345 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-06-12 |
4 |
AS |
$24.00 |
$240,000 |
D/D |
(10,000) |
17,643 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-06-12 |
4 |
OE |
$10.29 |
$102,900 |
D/D |
10,000 |
27,643 |
|
- |
|
Simpson Todd E |
Chief Financial Officer |
|
2012-06-12 |
4 |
AS |
$23.97 |
$1,078,785 |
D/D |
(45,000) |
50,762 |
|
- |
|
Simpson Todd E |
Chief Financial Officer |
|
2012-06-12 |
4 |
OE |
$5.20 |
$234,000 |
D/D |
45,000 |
95,762 |
|
- |
|
Simpson Todd E |
Chief Financial Officer |
|
2012-06-08 |
4 |
AS |
$22.97 |
$803,950 |
D/D |
(35,000) |
50,762 |
|
- |
|
Simpson Todd E |
Chief Financial Officer |
|
2012-06-08 |
4 |
OE |
$5.20 |
$182,000 |
D/D |
35,000 |
85,762 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-06-07 |
4 |
AS |
$22.50 |
$305,235 |
D/D |
(13,566) |
17,643 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-06-07 |
4 |
OE |
$10.29 |
$139,594 |
D/D |
13,566 |
31,209 |
|
- |
|
Gryska David W |
Director |
|
2012-06-05 |
4 |
S |
$19.75 |
$158,000 |
D/D |
(8,000) |
11,500 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-05-18 |
4 |
AS |
$20.80 |
$1,395,616 |
D/D |
(64,800) |
17,643 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-05-18 |
4 |
OE |
$4.45 |
$288,360 |
D/D |
64,800 |
34,667 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-05-16 |
4 |
AS |
$20.80 |
$4,160 |
D/D |
(200) |
17,643 |
|
- |
|
Rosenberg Morris |
EVP, Process Sciences |
|
2012-05-16 |
4 |
OE |
$4.45 |
$890 |
D/D |
200 |
17,843 |
|
- |
|
Reynolds Thomas C |
Chief Medical Officer |
|
2012-05-15 |
4 |
AS |
$19.75 |
$18,743 |
D/D |
(949) |
31,073 |
|
- |
|
Reynolds Thomas C |
Chief Medical Officer |
|
2012-05-15 |
4 |
OE |
$8.24 |
$7,820 |
D/D |
949 |
32,022 |
|
- |
|
Reynolds Thomas C |
Chief Medical Officer |
|
2012-04-25 |
4 |
AS |
$19.75 |
$790,000 |
D/D |
(40,000) |
31,073 |
|
- |
|
Reynolds Thomas C |
Chief Medical Officer |
|
2012-04-25 |
4 |
OE |
$8.24 |
$329,600 |
D/D |
40,000 |
71,073 |
|
- |
|
Dobmeier Eric |
Chief Operating Officer |
|
2012-04-25 |
4 |
AS |
$19.95 |
$498,750 |
D/D |
(25,000) |
68,073 |
|
- |
|
1805 Records found
|
|
Page 47 of 73 |
|
|